Chronic Idiopathic Constipation
36
0
0
26
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Published Results
23 trials with published results (64%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
11.1%
4 terminated out of 36 trials
86.7%
+0.2% vs benchmark
58%
21 trials in Phase 3/4
88%
23 of 26 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 26 completed trials
Clinical Trials (36)
"Efficacy and Safety of Linaclotide in Chronic Constipation"
This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy Participants
Efficacy and Safety of Vibrant Capsule vs. Placebo for the Treatment of Chronic Idiopathic Constipation
Efficacy and Safety of Vibrant Capsule vs. Vibrant Placebo for the Treatment of Chronic Idiopathic Constipation (CIC)
Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic Constipation
A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults
BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults
An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults
Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo
SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation
12-Week Study of Plecanatide for CIC (The CIC3 Study)
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®
An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation
An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation
Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)
Efficacy of Linaclotide to Senna for CIC
12-Week Study of Plecanatide for CIC (The National CIC3 Study)
The Plecanatide Chronic Idiopathic Constipation (CIC) Study